PRAX
HEALTHCAREPraxis Precision Medicines Inc
AI Insight
What's Moving PRAX Today?
No stock-specific AI insight has been generated for PRAX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$37.19$366.52
$305.37
Fundamentals
Market Cap$8.5B
P/E Ratio—
EPS$-13.39
Dividend Yield—
Dividend / Share—
ROE-35.3%
Profit Margin—
Debt / Equity—
Trading
Volume519K
Avg Volume (10D)—
Shares Outstanding27.9M
PRAX News
23 articles- Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy DesignationAdvfn·Jun 22, 2026
- Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function VariantsThe Manila Times·Jun 22, 2026
- FDA gives Praxis seizure drug Breakthrough Therapy statusStock Titan·Jun 22, 2026
- Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack UpYahoo Finance·Jun 15, 2026
- BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX)Yahoo Finance·Jun 11, 2026
- Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study FindingsYahoo Finance·Jun 5, 2026
- Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·Jun 4, 2026
- NewLimit’s $435M megaround; Lilly’s busy dealmaking weekBiopharmadive·Jun 3, 2026
- Praxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy PipelineYahoo Finance·Jun 3, 2026
- Stock Indexes Post New Record Highs Amid AI EnthusiasmBarchart·Jun 2, 2026
- The Shocking Twist That Sent This Seizure-Focused Biotech Into A DiveYahoo Finance·Jun 2, 2026
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 2, 2026
- Sector Update: Healthcare Stocks Softer Late AfternoonYahoo Finance·Jun 2, 2026
- Stocks Push Higher on US Labor Market Strength and AI SpendingBarchart·Jun 2, 2026
- Stocks Pressured by Uncertainty of US-Iran Ceasefire ProspectsBarchart·Jun 2, 2026
- Wall Street Set to Open Lower in Tuesday Trading as Investors Look for Signs of Middle East Peace Deal, Await Key Labor DataYahoo Finance·Jun 2, 2026
- PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline CandidatesStocktwits·Jun 1, 2026
- Praxis Precision Medicines Provides Vormatrigine Program UpdateYahoo Finance·Jun 1, 2026
- FDA Acceptance of Two CNS NDAs Might Change The Case For Investing In Praxis Precision Medicines (PRAX)Yahoo Finance·Jun 1, 2026
- This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterMotley Fool·May 31, 2026
- Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 MillionMotley Fool·May 31, 2026
- 10 Best Biotech Stocks to Invest In According to Billionaire Steve CohenInsider Monkey·May 11, 2026
- Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathyGlobeNewswire Inc.·Apr 6, 2026
All 23 articles loaded
Price Data
Open$298.50
Previous Close$305.37
Day High$308.01
Day Low$296.36
52 Week High$366.52
52 Week Low$37.19
52-Week Range
$37.19$366.52
$305.37
Fundamentals
Market Cap$8.5B
P/E Ratio—
EPS$-13.39
Dividend Yield—
Dividend / Share—
ROE-35.3%
Profit Margin—
Debt / Equity—
Trading
Volume519K
Avg Volume (10D)—
Shares Outstanding27.9M
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—